Clinical Trial Update: Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial of ruxolitinib for early lung dysfunction after hematopoietic stem cell transplant was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO) | Phase 2 | Status: TERMINATED